Evidence map›Paper›PMID 42248561›Full record

ArticleMolecules and cells2026

Oxidative stress drives liver failure during in vivo partial reprogramming.

Hee-Ji Eom, Beom-Ki Jo, Jumee Kim, Hyuk-Jin Cha

Abstract read
In one paragraph

Article in Molecules and cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hee-Ji EomCollege of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Beom-Ki JoCollege of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Jumee KimCollege of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea.
Hyuk-Jin ChaCollege of Pharmacy, Seoul National University, Seoul, Republic of Korea; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea. Electronic address: hjcha93@snu.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vivo reprogramming using the Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC; OSKM) enables tissue regeneration but raises major safety concerns when factor expression is sustained. Here, using a doxycycline-inducible OSKM mouse model, we show that prolonged systemic OSKM induction causes early lethality associated with hepatocyte dedifferentiation and oxidative stress in the absence of tumor formation. Single-nucleus RNA sequencing revealed activation of reactive oxygen species (ROS), oxidative stress, and NRF2 signaling pathways in hepatocytes. Increased ROS production in hepatocytes, together with the higher resistance of female mice and sex-dependent differences in antioxidant response programs, implicates oxidative stress as a primary driver of mortality during sustained OSKM expression. Importantly, antioxidant treatment with N-acetylcysteine (NAC) alleviated oxidative stress and significantly improved survival without impairing reprogramming-associated cellular plasticity. These findings establish oxidative stress as a key driver of liver failure during sustained in vivo reprogramming and provide a mechanistic rationale for cyclic induction strategies.

Indexed as

Cellular ReprogrammingLiver FailureOxidative StressAcetylcysteineAnimalsAntioxidantsFemaleHepatocytesKruppel-Like Factor 4MaleMiceNF-E2-Related Factor 2Reactive Oxygen SpeciesSignal TransductionAcetylcysteineAntioxidantsKlf4 protein, mouseKruppel-Like Factor 4NF-E2-Related Factor 2Reactive Oxygen SpeciesIn vivo reprogrammingLiver failureN-acetylcysteineOxidative stressReactive oxygen species

Identifiers

PMID42248561
PMCPMC13330666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.